Pharmacorp Rx Inc. · TSXV:PCRX
Pharmacorp Rx — Investor Presentation (September 2025)
19 slides from Pharmacorp Rx's investor presentation, Sep 8, 2025
Slide 1: Investor Presentation Q2 2025
Investor Presentation Q2 2025
Slide 2: Disclaimers: Forward-Looking Information and Non-IFRS Financial Measures
Disclaimers: Forward-Looking Information, Prospective Investor Disclaimer, Industry and Market Data and Non-IFRS Financial Measures Forward-Looking Information: This presentation contains “forward-looking information” regarding PharmaCorp within the meaning of applicable Canadian securities legislat
Slide 3: Disclaimers: Prospective Investor, Industry Data and Non-IFRS Measures
Disclaimers: Forward-Looking Information, Prospective Investor Disclaimer, Industry and Market Data and Non-IFRS Financial Measures Prospective Investor Disclaimer: This presentation does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction. Any o
Slide 4: Pharmacy Ownership Models
PHARMACY OWNERSHIP MODELS Spectrum of Pharmacy Ownership Models Franchised/ Corporate- Corporate- Banner Pure Owned Affiliated Co-ops Independent >2,000 3
Slide 5: PharmaChoice Canada's Structural Challenge (Pre-PharmaCorp)
PHARMACHOICE CANADA’S STRUCTURAL CHALLENGE (PRE-PHARMACORP) 1,100+ Independent Pharmacies and Growing 1,150 1,112 1 1,100 1,075 1,050 40+ 1,012 1,000 952 950 895 New Stores ROFR Without Capital 900 Joining PharmaChoice Canada (“PCC”) held the right of first Annually refusal on all member stores but
Slide 6: Company Overview
COMPANY OVERVIEW PharmaCorp Rx (TSXV:PCRX) is a Canadian pharmacy consolidator, currently operating Stores four pharmacies under the PharmaChoice Canada banner Stores Under SPA Holds an exclusive right-of-first-refusal to Stores Under LOI acquire 1,100+ pharmacies under a strategic alliance agre
Slide 7: Our Sustainable Competitive Advantage
OUR SUSTAINABLE COMPETITIVE ADVANTAGE Exclusive ROFR on Growing Pipeline: 40–50 PCC Proven 1,100+ Stores +40 New Stores/ Stores Turn Over Ability to Acquire Ann. Added to Annually = Built-In Stores with a PCC Banner Deal Flow Unique Offering 6
Slide 8: Key Highlights
KEY HIGHLIGHTS A National Consolidator of Choice for the Highly Fragmented Pharmacy Industry • Demonstrated ability to effectively identify, acquire and integrate pharmacies into network Operating in a Stable, Resilient and Growing Industry • A recession-resistant industry bolstered by favourable de
Slide 9: A Sector Built for Stability & Growth
A SECTOR BUILT FOR STABILITY & GROWTH Why Pharmacy? Percent of Canadians Aged 65+ 1 19.8% 18.9% Recession-Resilient Sector: 18.0% Essential healthcare spend drives stable cash flows 17.1% 16.4% 15.6% Canada’s Aging Population: Prescription demand accelerates after ages 45+ and 65+ 2014 2015 2016 201
Slide 10: Seller Rationale: Post-Acquisition Value Creation
SELLER RATIONALE Post-Acquisition Value Creation Flexible Exit Options Front Shop Growth Opportunity: Pharmacists focus patient outcomes, leaving the front shop under-managed and under-optimized Our Approach: Re-energize front shop operations by leveraging PharmaChoice Canada’s Portfolio Exit Plan
Slide 11: Our Differentiated Co-Ownership Model
OUR DIFFERENTIATED CO-OWNERSHIP MODEL Subsidiary Ownership (vs. ParentCo Equity) Direct Alignment: Pharmacists clearly see how their Pharmacist Labour Market Outlook (2024 – 2033) 1 decisions impact financial results Tangible Rewards: Financial upside tied directly to their Pharmacists are pro
Slide 12: Our Ideal Acquisition Profile
OUR IDEAL ACQUISITION PROFILE ~$2mm+ ~$350K+ ~35,000+ Annual Revenue Adj. EBITDA 1 Annual Script Count Funding Staffing Acquisition paid partially or Managing pharmacist in full with PCRX Share with store-level Consideration ownership interest 1. Adjusted EBITDA (Pre-IFRS 16, 4-Wall basis) 11
Slide 13: Q2 Highlights
Q2 HIGHLIGHTS Same Store Script Same Store Sales Adjusted EBITDA 1 Count Growth Growth Q1 3.2% 3.9% $707.4K Q2 3.5% 11.3% $688.0K Q3 Q4 1. Adjusted EBITDA (Pre-IFRS 16, 4-Wall basis). See appendix for supporting detail Please note that retail pharmacies experience seasonality, with higher prescripti
Slide 14: Experienced Executive & Governance Team
EXPERIENCED EXECUTIVE & GOVERNANCE TEAM Senior Management Team and Board of Directors Co-founder of PCRX Alan Simpson Previously co-founded Hospitality Network Canada and StorageVault Canada (TSX: SVI.T) Executive Chairman, Director StorageVault is Canada’s largest self-storage company with ov
Slide 15: Appendix
PharmaCorp Rd Appendix
Slide 16: Adjusted EBITDA Reconciliation
ADJUSTED EBITDA RECONCILIATION Q1 Q2 100% Store-Level Net Income Before Tax 1 525,534 512,688 + Depreciation & Amortization 187,097 188,277 + Interest on Long Term Debt 5,565 5,352 + Lease Interest 8,141 7,893 +/- Other Adjustments 2 7,300 - - Actual Lease Payments (26,252) (26,252) Adjusted EBITDA
Slide 17: Capital Structure
CAPITAL STRUCTURE Common Shares % of Undiluted Total Other Shareholders 1 102,636,125 87.5% Board & Executive Team 14,659,400 12.5% Total Shares 117,295,525 100.0% 1. Strong Alignment with PCC Network: ~86% of July 2024 $0.40/share retail raise came from the President’s List (PCC pharmacy owners, em
Slide 18: Q2 Balance Sheet Highlights
Q2 BALANCE SHEET HIGHLIGHTS In C$ 000’s Assets Liabilities Cash 9,564 Accounts payable and accruals 1,969 Accounts receivable 643 Taxes payable 21 Inventories 1,693 Current portion of lease liabilities 76 Prepaid expenses and deposits 56 Current portion of long-term debt 75 Total Current Assets 11,9
Slide 19: For More Information, Please Contact Us
19 For More Information, Name: Alan Simpson Phone: +1 (306) 536-3771 Please Contact Us Email: simpsonvideo@sasktel.net
PharmaCorp Rx — Investor Presentation (September 2025) on 6ix